http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102328471-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5058 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5035 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5023 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2020-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102328471-B1 |
| titleOfInvention | Composition for preventing or treating diabetic neuropathy comprising LCN2 inhibitor |
| abstract | The present invention relates to a composition for preventing or treating diabetic nerve damage disease comprising an LCN2 inhibitor as an active ingredient. ), the expression of LCN2 was increased, and it was confirmed that the symptoms of diabetic nerve damage disease were improved when the LCN2 gene was deficient. Therefore, in the present invention, the LCN2 inhibitor is a diabetic nerve damage disease, specifically pain, numbness, numbness, rats, foot ulcers, tachycardia at rest, orthostatic hypotension (dizziness, dizziness, syncope, visual disturbance, weakness, headache) , suggested the possibility that it will be useful as a preventive and therapeutic agent for symptoms such as cardiac denervation syndrome, constipation, diabetic diarrhea, bladder dysfunction, sexual dysfunction, thermoregulation disorder, hypoglycemia anaesthesia, and pupil dysfunction. |
| priorityDate | 2019-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 66.